Navigation Links
Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have identified a previously unknown function of APOBEC3G (A3G), a protein that acts against HIV, a finding that may lead to new approaches for controlling HIV infection.

The work is published today, Oct. 2, 2006, in Proceedings of the National Academy of Sciences, USA.

The research, conducted by scientists in the laboratory of GIVI Director Warner C. Greene, MD, PhD, explains why CD4 T cells ?the immune system cells targeted by HIV -- are sometimes so susceptible to HIV infection and at other times are highly resistant.

Scientists have known that resistant CD4 T cells, called "resting cells," are made up predominantly of CD4+ T cells that are in an inactive state, awaiting a stimulus to move into action. In these cells, A3G blocks HIV at an early step in its life cycle. However, when resting CD4 T cells are stimulated by a foreign protein or other signal, A3G is rapidly recruited into large RNA protein complexes within the cells. This change neutralizes the anti-HIV properties of A3G, opening the door to HIV infection.

In the current study, the researchers set out to decipher the protein and RNA components of the A3G RNA protein complexes. In so doing, Ya-Lin Chiu, PhD, a postdoctoral fellow in Greene's laboratory, determined that the complexes help to prevent a threat within cells posed by a class of "jumping genes," or retro-elements, which are sequences of DNA that change position within the genome, causing mutations, activating or inactivating other genes, or duplicating themselves, thereby increasing the quantity of DNA in each cell.

As with HIV, the replication and movement of these retro-elements to new chromosomal sites with potentially damaging effect involves copying DNA into RNA and then back into DNA again. The A3G RNA protein complex, Chiu determined, interrupts this retro-element replication cycle by binding the retro-element RNAs and
'"/>

Source:University of California - San Francisco


Page: 1 2

Related biology news :

1. Gladstone investigators discover how resting T cells avoid HIV infection
2. MUHC investigators search for the root of sexual pain in women
3. Fox Chase Cancer Center scientists identify immune-system mutation
4. Researchers identify target for cancer drugs
5. Scientists identify genetic pathways essential to RNA interference
6. Scientists identify molecular events that drive cell senescence
7. Scientists identify new model Of NK cell development
8. Chemists identify key gene in development of type 1 diabetes
9. Yale researchers identify molecule for detecting parasitic infection in humans
10. Wisconsin researchers identify sleep gene
11. Chemists identify immune system mechanism for methamphetamine binges
Post Your Comments:
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... attained very promising results on their initial investigations of a ... mass spectrometry of a single drop of blood serum, the ... of the patients tested. The results can be found online ... . "Because ovarian cancer is a disease of ...
... As much as 12 percent of the worlds human-caused greenhouse ... charcoal-like substance made from plants and other organic materials. Thats ... and materials were burned to generate energy, concludes a study ... calculations show that biochar can play a significant role in ...
... marine mosasaur Platecarpus , lived in the Cretaceous Period some ... an eel. That theory is debunked in a new paper published ... of scientists have reconceived the animal,s morphology, or body plan, based ... Los Angeles County. The paper was co-authored by ...
Cached Biology News:Initial trials on new ovarian cancer tests exhibit extremely high accuracy 2Charcoal takes some heat off global warming 2Charcoal takes some heat off global warming 3Charcoal takes some heat off global warming 4Charcoal takes some heat off global warming 5Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster 2
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Nine field ... Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the field ... lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible has ...
(Date:8/3/2015)... , Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... focused on the development of autologous cell therapies, announced today ... at the InvestMNT conference held in Minneapolis, Minnesota ... local time. Hall,s presentation will highlight RepliCel,s 18-month milestones including ... Europe , clinical data from both RCT-01 ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... TGH to Enhance Clinical Skills,Development, DENVER, Nov. ... partnership with the University of South Florida (USF) ... Health hospital,partners and for local and national health ... Center is located at Tampa,General Hospital, a major ...
... 10 NeurogesX, Inc.,(Nasdaq: NGSX ), a ... management therapies, announced today that,Anthony DiTonno, President and ... Rodman & Renshaw 10th Annual Healthcare Conference in ... DiTonno and Stephen Ghiglieri,Chief Financial Officer, will also ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
Cached Biology Technology:Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: